Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Home › Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca .

27.11	(CFI-ZCT1J02)
27.11
27.11	QUICKSILVER 8/S 130
27.11
27.11	Laurene LaVallis Key To Our Love 7 US
27.11	THE SCOPE AFTER DARK LP
27.11
27.11	DVD
More »

je.st